文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

瑞典老年人新冠疫苗接种后罕见不良事件的全国注册研究

Rare adverse events after COVID-19 vaccination among Swedish older adults-evidence from a nationwide register-based study.
PubMed 文献 · Vaccine · 2026-05-16

结果显示多数结局风险未升高,但突发性感音神经性听力损失、风湿性多肌痛和带状疱疹在部分风险窗内风险比轻度升高,整体获益-风险特征不变。

要点

  • 多数潜在罕见不良事件在接种后风险未显著升高。
  • 突发性感音神经性听力损失在每剂次后180天内风险比升高。
  • 风湿性多肌痛和带状疱疹在部分剂次或敏感性分析中风险比轻度升高。

核心结论

  • 新冠疫苗在老年人中总体安全,所评估的潜在罕见不良事件发生率极低。
  • 突发性感音神经性听力损失、风湿性多肌痛和带状疱疹的相对风险轻度升高,但不改变老年人接种的总体获益-风险特征。

研究设计与样本

  • 比较接种与未接种者,采用Cox回归估计风险比(HR)及95%置信区间(95%CI),调整潜在混杂因素。
  • 评估每剂次后1-30、31-60和61-180天风险窗内的多种潜在不良事件。

主要发现

  • 多数结局未观察到风险比升高。
  • 突发性感音神经性听力损失在每剂次后180天内风险比升高:第1剂1.60(95%CI 1.15-2.24),第2剂1.43(95%CI 1.03-1.99),第3剂1.61(95%CI 1.05-2.46),三个风险窗估计相似。
  • 风湿性多肌痛在第2剂后风险比1.14(95%CI 1.04-1.24),第3剂后1.16(95%CI 1.03-1.30),较晚时间窗风险比更高。
  • 带状疱疹在加入初级卫生保健就诊的敏感性分析中风险比升高:第1剂1.19(95%CI 1.07-1.31),第2剂1.31(95%CI 1.19-1.43),第3剂1.42(95%CI 1.26-1.60)。
  • 多发性硬化在较长洗脱期的敏感性分析中第3剂后风险降低,但主分析未观察到此现象。

临床怎么用

  • 老年人接种新冠疫苗总体安全,罕见不良事件发生率极低,支持继续接种。
  • 对接种后出现突发性感音神经性听力损失、风湿性多肌痛或带状疱疹症状者,可考虑与接种的时间关联并评估。

局限性

  • 观察性研究设计可能残余混杂。
  • 部分结局仅在敏感性分析中观察到风险升高。
  • 原文未报告具体发生率数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: COVID-19 vaccinations have saved millions of lives, particularly among older adults. Rare potential adverse events have been reported in case reports, but risks among older adults remain unclear. This study assessed risks of selected potential adverse events in this population. METHODS: We included more than 2 million Swedish adults ≥65y in a nationwide register-based cohort. Post-vaccination risks were assessed for herpes zoster (HZ), encephalitis, myelitis and encephalomyelitis, multiple sclerosis (MS), myasthenia gravis, cranial nerve palsy, sudden sensorineural hearing loss (SSNHL), postinfectious arthritis and polymyalgia rheumatica (PMR) in several risk windows (1-30, 31-60, and 61-180 days) after each vaccine dose. Hazard ratios (HRs) with 95% confidence intervals (95%CIs) compared with unvaccinated were estimated by Cox regression adjusted for potential confounders. Sensitivity analyses included adding primary health care (PHC) visits, and applying analysis-specific 5-year disease-free wash-out periods. RESULTS: No increased HRs were observed for most outcomes. SSNHL showed increased HRs within 180 days after each dose [1.60 (95%CI 1.15-2.24); 1.43 (1.03-1.99); 1.61 (1.05-2.46) for dose 1, 2 and 3], with similar estimates across all three risk windows. Increased HRs were also seen for PMR after dose 2 [1.14 (1.04-1.24)] and dose 3 [1.16 (1.03-1.30)], with higher HRs during later time windows. HZ showed increased HRs in the sensitivity analysis with PHC visits, [1.19 (1.07-1.31); 1.31 (1.19-1.43); 1.42 (1.26-1.60) for dose 1, 2 and 3]. MS showed reduced risk after dose 3 in the sensitivity analysis with longer wash-out (targeting incident MS), but not in the main analysis (potential relapses included). CONCLUSIONS: COVID-19 vaccines are generally safe in older adults, with very low incidence of the potential rare adverse events assessed. Slightly increased relative risks for SSNHL, PMR and HZ were observed, but these findings do not alter the overall benefit-risk profile of COVID-19 vaccination in older adults.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Xu Y, Nyberg F, Marking U, et al. Rare adverse events after COVID-19 vaccination among Swedish older adults-evidence from a nationwide register-based study. Vaccine. 2026. PMID: 42142527. doi:10.1016/j.vaccine.2026.128724

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。